

# Palladium-Catalyzed C-H Activation: A Versatile Gateway to Biologically Active Fused 1,2,3-Triazole (Dihydro)quinolines

D. Allevi<sup>a</sup>, K. Ullah<sup>b</sup>, A. Goggiamani<sup>b</sup>, G. Fabrizi<sup>b</sup>, F. Marrone<sup>b</sup>, A. Iazzetti<sup>c</sup>, V. Barbera<sup>a</sup>, D. Gentile<sup>a</sup>, M. Galimberti<sup>a</sup>.

<sup>a</sup> *Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, Ed 41, Via Bassini 6, Milano 20133, Italy.*

<sup>b</sup> *Department of Chemistry and Technology of Drugs, Sapienza-University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.*

<sup>c</sup> *Dipartimento di Scienze Biotecnologiche di Base Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Campus di Roma, Largo Francesco Vito 1, 00168 Rome, Italy,*

Presenting author: [dario.allevi@polimi.it](mailto:dario.allevi@polimi.it) Presenting author: [dario.allevi@polimi.it](mailto:dario.allevi@polimi.it)

The development of novel nitrogen-containing polycyclic heterocycles represents a milestone of modern medicinal chemistry, as these structures often possess pharmaceutical activity. Among these, 1,2,3-triazole-fused quinolines and dihydroquinolines were subject to a rising attention from researchers due to the therapeutic potential of both the quinoline and 1,2,3-triazole moieties. Molecules containing those frameworks have already shown promise as kinase inhibitors (Qiao et al., 2019; Zhang et al., 2023), diabetics II inhibitors (Avula et al., 2023), and antibacterials (Mukusheva et al., 2025) activities.

In this work (Ullah et al., 2025), we developed a simple and efficient synthetic approach toward structurally diverse fused polycyclic [1,2,3]triazolo[4,5-c]quinolines and 4,5-dihydro-[1,2,3]triazolo[4,5-c]quinolines.

The protocol is based on an intramolecular palladium-catalyzed C-H activation that bears together high atom economy and broad functional group tolerance. By fine-tuning the reaction conditions, we achieved high yields and selective access to those systems.

To further investigate the pharmaceutical utility of this method, Suzuki cross-coupling, Buchwald amination, and selective reduction were tested on those scaffolds.

These transformations enable the synthesis of complex derivatives with desired properties, serving as a tool for drug discovery processes.